In the BioHarmony Drug Report Database
Sugammadex
Bridion (sugammadex) is an oligosaccharide pharmaceutical. Sugammadex was first approved as Bridion on 2008-07-25. It has been approved in Europe to treat neuromuscular blockade. Bridion’s patents are valid until 2026-01-27 (FDA).
Trade Name
|
Bridion |
|---|---|
Common Name
|
sugammadex |
ChEMBL ID
|
CHEMBL2111107 |
Indication
|
neuromuscular blockade |
Drug Class
|
Image (chem structure or protein)